U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical ...

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA.

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

The drug's safety profile was consistent with that found in prior studies, with no new safety signals identified.

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...